ReviewClinical rheumatology2015
Enthesitis-related arthritis.
Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 54 citations in OpenAlex.
- Damage Control in JIA: A Call to Action in Resource-Limited Settings.Indian journal of pediatrics · 2025Article
- Clinical Impact of HLA-B27 on Juvenile Idiopathic Arthritis: Eighteen Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.ACR open rheumatology · 2025Article
- Presentation of enthesitis-related arthritis and juvenile-onset spondyloarthritis: a cross-sectional study in a pediatric and adult clinic.Advances in rheumatology (London, England) · 2024Article
- A clinical perspective on imaging in juvenile idiopathic arthritis.Pediatric radiology · 2024Review
- IL-36γ in enthesitis-related juvenile idiopathic arthritis and its association with disease activity.Clinical and experimental immunology · 2022Article
- Joint involvement, disease activity and quality of life in pediatric Crohn's disease - a cross-sectional study.Pediatric rheumatology online journal · 2022Observational
- Successful treatment in a child with enthesitis-related arthritis involving the sternoclavicular joint: a case report.BMC pediatrics · 2019Article
- Update on the management of uveitis in children: an overview for the clinician.Expert review of ophthalmology · 2019Article
- Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre.Pediatric rheumatology online journal · 2018Article
- The performance of classification criteria for juvenile spondyloarthropathies.Rheumatology international · 2017Article
- Juvenile Idiopathic Arthritis.Balkan medical journal · 2017Article
- Management of Juvenile Idiopathic Arthritis: A Clinical Guide.Paediatric drugs · 2016Review
- Juvenile Spondyloarthropathies.Current rheumatology reports · 2016Review
- Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status.Frontiers in microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic arthritis of childhood. Currently, it is characterized by seven categories. The enthesitis-related arthritis (ERA) category usually affects boys older than 6 years and presents with lower limb asymmetrical arthritis associated with enthesitis. Later, these children can develop inflammatory lumbosacral pain (IBP). These children are at risk of developing acute anterior uveitis. A recently devised disease activity index, Juvenile Spondyloarthropathy Disease Activity Index (JSpADA), has been validated in retrospective cohorts. The corner stone of treatment is NSAIDs, local corticosteroid injections, and exercise. Methotrexate and sulfasalazine can be used for peripheral arthritis while anti-tumor necrosis factor (TNF) agents are sometimes used to treat refractory enthesitis and sacroiliitis. Almost two third of patients with ERA have persistent disease and often have impairments in their quality of life. The presence of hip or ankle arthritis and a family history of spondyloarthropathy or polyarticular joint involvement at onset are associated with poorer prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.